Company performance
Current Price
as of Jun 13, 2025$2.31
P/E Ratio
37.44
Market Cap
$131.35M
Description
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBDTX
- Price$2.31-4.94%
Trading Information
- Market cap$131.35M
- Float76.14%
- Average Daily Volume (1m)1,128,144
- Average Daily Volume (3m)3,520,737
- EPS$0.08
Company
- Revenue$70.00M
- Rev growth (1yr)N/A
- Net income$56.54M
- Gross margin99.88%
- EBITDA margin78.02%
- EBITDA$54.62M
- EV-$41.42M
- EV/Revenue-0.59
- P/E37.44
- P/S1.90
- P/B0.93
- Debt/Equity15.25